enVVeno Medical
NVNO
22 hedge funds and large institutions have $13.5M invested in enVVeno Medical in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 3 closing their positions.
3,985% more call options, than puts
Call options by funds: $2.7M | Put options by funds: $66K
0.01% more ownership
Funds ownership: 0.63% → 0.64% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
2% less capital invested
Capital invested by funds: $13.7M → $13.5M (-$232K)
8% less funds holding
Funds holding: 24 → 22 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
+$769K |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$430K |
| 3 |
BlackRock
New York
|
+$5.82K |
| 4 |
AMCA
Arthur M. Cohen & Associates
Northbrook,
Illinois
|
+$5.63K |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$491K |
| 2 |
Two Sigma Investments
New York
|
-$188K |
| 3 |
Two Sigma Advisers
New York
|
-$173K |
| 4 |
Morgan Stanley
New York
|
-$115K |
| 5 |
Renaissance Technologies
New York
|
-$94K |
NVNO Hedge Fund Activity: Q1 2022 in Review
22 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in enVVeno Medical (NVNO) for Q1 2022, worth a combined $13.5M — down 1.7% from $13.7M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NVNO and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was ACT Capital Management, adding an estimated $769K. The largest seller was Velan Capital Investment Management, exiting entirely with an estimated $491K sold.
- 22 institutional investors held enVVeno Medical (NVNO) as of Q1 2022, down from 24 in Q4 2021.
- Funds reported $13.5M of enVVeno Medical stock for Q1 2022, down 1.7% quarter-over-quarter.
- 1 fund opened new enVVeno Medical positions in Q1 2022 and 3 closed out, a net change of -2 holders.
- The largest enVVeno Medical buyer in Q1 2022 was ACT Capital Management, an estimated $769K added.
- The largest enVVeno Medical seller in Q1 2022 was Velan Capital Investment Management, an estimated $491K sold.
Based on aggregated 13F filings for Q1 2022.